Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 AlteredExpression BEFREE In five of the six unmutated CLLs, the DLBL clones evolved from CLL tumorclones and the VH genes expressed by DLBLs were also unmutated. 14671632

2004

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE The expression level of TOSO was significantly correlated with Binet staging, IGVH mutation status, age, and time to treatment in CLL. 21133733

2011

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE Mutated IGHV was detected in 71·2% of Taiwanese CLL and IGHV3-23 was the most frequently used gene. 31230372

2019

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE In this study, using ChIP-sequencing, we identified EZH2 and H3K27me3 target genes in two prognostic subgroups of CLL with distinct prognosis and outcome, i.e., cases with unmutated (U-CLL, n = 6) or mutated IGHV genes (M-CLL, n = 6). 31216925

2019

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE We retrospectively analyzed 463 patients with CLL with available immunoglobulin heavy-chain variable (IGHV) gene status and B-cell receptor (BCR) configuration [heavy-chain complementary-determining region 3 (HCDR3)], of whom thirty-six developed ITP, according to previously defined criteria. 22322667

2012

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE We devised a biomarkers-only CLL prognostic system based on the two most important prognostic parameters in CLL (i.e., IGHV mutational status and fluorescence in situ hybridization [FISH] cytogenetics), separating three different risk groups: (1) low-risk (mutated IGHV + no adverse FISH cytogenetics [del(17p), del(11q)]); (2) intermediate-risk (either unmutated IGHV or adverse FISH cytogenetics) and (3) high-risk (unmutated IGHV + adverse FISH cytogenetics). 28120419

2017

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 AlteredExpression BEFREE TAp63 mRNA levels were higher in CLL with unmutated IGHV. 24117128

2013

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE We studied whether bendamustine (BENDA) alone or with rituximab (RIT) modifies <i>in vitro</i> expression of apoptosis-involved genes and proteins of chronic lymphocytic leukemia (CLL) cells depending on IGVH mutational status. 30187811

2019

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE CD49d, the alpha-chain of the integrin heterodimer α4β1, was identified among the strongest predictors of overall survival (OS) in chronic lymphocytic leukemia (CLL), along with IGHV mutational status and deletion of the 17p chromosome involving TP53. 27109509

2016

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE The mutational status of the immunoglobulin heavy chain variable (IGHV) genes identifies two subsets of CLL with different outcomes. 23531595

2013

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE We analyzed the correlation between well-established biological parameters of prognostic relevance in B-cell chronic lymphocytic leukemia (CLL) [i.e. mutational status of the immunoglobulin heavy chain variable region (IgVH), ZAP-70 and CD38 expression] and serum levels of B cell-activating factor (BAFF of the TNF family) by evaluating the impact of these variables on the time to first treatment (TFT) in a series of 169 previously untreated CLL patients in Binet stage A. 20546021

2010

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE We previously identified LDOC1 as one of the most significantly differentially expressed genes in untreated chronic lymphocytic leukemia (CLL) patients with respect to the somatic mutation status of the immunoglobulin heavy-chain variable region genes. 21310924

2011

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE The pattern and location of insertions/duplications or deletions in CLL and their restriction to mutated IGHV rearranged genes strongly suggests that they resulted from somatic hypermutation. 16783849

2006

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients. 31054420

2019

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE To further characterize the biological features of this disease, we performed IgVH gene mutational status, FISH and high-resolution comparative genomic hybridization (HR-CGH) analysis in 17 cases of CLL/PL. 17410523

2007

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 AlteredExpression BEFREE Here, we evaluated the reactivity of a panel of different CLL recombinant antibodies (rAbs) encoded by the most commonly expressed IGHV genes with a panel of selected viral and bacterial pathogens. 22234695

2012

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE The two major subsets of CLL are biologically distinct, being derived from B cells at different stages of differentiation and carrying unmutated (U-CLL) or mutated (M-CLL) IGHV genes. 25048780

2014

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Highly homologous B-cell receptors, characterized by non-random combinations of immunoglobulin heavy-chain variable (IGHV) genes and heavy-chain complementarity determining region-3 (HCDR3), are expressed in a recurrent fraction of patients affected by chronic lymphocytic leukemia (CLL). 21897877

2011

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE On a cohort of 110 patients with CLL treated with first-line fludarabin, cyclophosphamide, and rituximab treatment compared with 33 untreated (watch and wait) patients with CLL, we report more frequent complex karyotypes (34 vs 15%; P = .05), unmutated IGHV (70 vs 21%; P < .0001), ATM deletion (25 vs 6%, P = .02), and NOTCH mutation (3 vs 17%, P = .04). 27678008

2017

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE Taking advantage of a population of 406 untreated Chinese patients with CLL at early and advanced stage of disease, we identified the strongest prognostic markers of TTFT and, subsequently, in a cohort of 173 patients who had complete data for all 3 variables, we integrated the data of traditional staging system, cytogenetic aberrations, and mutational status of immunoglobulin heavy chain variable region (IGHV) in CLL-PI. 28091403

2017

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Therefore, a single RNA-seq assay can simultaneously yield gene expression profile, SNP and mutation information, as well as IGHV mutation status, and may one day be performed as a general test to capture multidimensional clinically relevant data in CLL. 25787252

2015

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE The strongest prognostic factor in chronic B-cell lymphocytic leukemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes. 24924909

2014

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 Biomarker BEFREE MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. 17107902

2006

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia. 21840049

2011

Entrez Id: 28402
Gene Symbol: IGHV3-69-1
IGHV3-69-1
CUI: C0023434
Disease: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
0.100 GeneticVariation BEFREE These agents lead to improved outcomes in CLL, even among patients with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. 30283014

2018